The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model

Senthilnathan Palaniyandi, Reena Kumari, Ethan Strattan, Timothy Huang, Jing Du, Natalya Hakim, Melissa V. Kesler, Gerhard C. Hildebrandt

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish
Pages (from-to)E39-E41
JournalAmerican Journal of Hematology
Volume95
Issue number2
DOIs
StatePublished - Feb 1 2020

Bibliographical note

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

Funding Information:
This study was funded by TAKEDA Pharmaceuticals U.S.A through IISR grant (SP and GCH). This research was supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility and Flow Cytometry and Cell Sorting Core Facility: Supported by the Markey Cancer Center and an NCI Center Core Support Grant (P30CA177558).

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model'. Together they form a unique fingerprint.

Cite this